secwatch.observer — SEC 8-K summary
======================================

Issuer:     COGNITION THERAPEUTICS INC (CGTX)
CIK:        0001455365
Form:       8-K
Filed at:   2023-03-23T23:59:59+00:00
Accession:  0001104659-23-035834
Event type: earnings
Sentiment:  neutral
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Cognition Therapeutics Reports Year End 2022 Financial Results and Provides Business Update
--------------------------------------------------------------------------------

- Completed enrollment in Phase 2 SEQUEL trial of CT1812 for mild-to-moderate Alzheimer's disease; topline results expected later 2023.
- Received FDA clearance for Phase 2 START study of CT1812 in early Alzheimer's disease and IND clearance for Phase 2 trial in geographic atrophy.
- Secured up to $35M equity commitment from Lincoln Park Capital and completed $6M follow-on public offering.
- Cash and cash equivalents $41.6M as of Dec 31, 2022, expected to fund operations into second half of 2024.
- Net loss for 2022 was $21.4M ($0.91 per share) compared to $11.7M ($3.13 per share) in 2021.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1455365/000110465923035834/0001104659-23-035834-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1455365/000110465923035834/tm2310284d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-23-035834

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer